Introduction
============

Inflammatory breast cancer (IBC) is a rare and aggressive clinicopathological entity of breast cancer, representing 1% to 6% of all types of breast cancer ([@ref-18]). In the tumor-node-metastasis (TNM) stage classification of breast cancer, IBC is categorized as T4d and clinically featured by the diffused duration of the skin with an erysipeloid edge, generally without underlying mass ([@ref-21]). Due to its rare incidence, IBC data is mainly acquired from small, single-centered, retrospective research, or extrapolated from randomized prospective studies or clinical experience of non-IBC patients ([@ref-32]).

Historically, IBC was treated by surgery and/or radiotherapy. The combination of surgery and radiotherapy leads to the improvement of overall survival ([@ref-8]). Radiotherapy is considered as the most effective local therapeutic modality only after surgery. However, the application of radiotherapy in IBC, optionally along with concurrent chemotherapy, is generally recommended only if radical resection (R0) is not achievable following primary systemic therapy ([@ref-4]; [@ref-5]; [@ref-31]). Notably, the great advance in modern and more effective neoadjuvant therapy has enhanced the partial or complete clinical response rate, and additionally, a considerable percentage of the previously unresectable subjects are proper for mastectomy ([@ref-3]; [@ref-16]). However, the survival benefit for postmastectomy radiotherapy (PMRT) has not been fully validated up to now ([@ref-25]). Current guidelines and recommendations for treatment of IBC stated that aggressive trimodality treatment, including PMRT, can be recommended, regardless of the response to systemic treatment ([@ref-7]; [@ref-13]). In addition, PMRT is under used in clinical practice ([@ref-23]). Therefore, it is urgent to precisely assess the prognostic role of PMRT in IBC.

In this research, a large cohort of IBC cases was selected from the Surveillance, Epidemiology, and End Results (SEER) dataset, followed by an investigation of the survival differences between PMRT and No-PMRT groups. We aimed at assessing factors correlated with the prognosis of IBC patients, highlighting the effects of PMRT on the outcomes of IBC patients.

Material and Methods
====================

Ethics statement
----------------

The National Cancer Institute's SEER program, initiated from 1973 and annually updated, uses population-based data to develop comprehensive sources ([@ref-15]). It covers approximately 30% of the US population throughout several geographic regions ([@ref-12]). The SEER Research Data Agreement was signed for accessing SEER information with the use of reference number 16462-Nov2016. Additionally, the research methods were performed to obtain data following approved guidelines. The data analysis was considered by the Office for Human Research Protection to be non-human subjects who were researched by the United States Department of Health and Human Services, as they were publicly available and de-identified. Thus, no approval was required by the institutional review board.

Study population
----------------

Patient data were acquired using the SEER database (Submission, November 2016). The SEER\*State v8.3.5 tool, released on March 6, 2018, was used to determine and select eligible patients. Additionally, the study duration ranged from 2010 to December 2013. The inclusion criteria were as follows: (1) only primary female IBC patients undergoing mastectomy were selected; (2) IBC was diagnosed in line with the International Classification of Disease for Oncology, Third Edition (ICD-O-3; coded as 8530/3). The exclusion criteria were listed in the following: (1) patients were burdened with multiple primary tumors; (2) patients were only clinically diagnosed; (3) patients without mastectomy; (4) patients with preoperative radiotherapy or unknown sequence of radiotherapy; (5) patients with incomplete important clinicopathological information, including age at diagnosis, race, 7th AJCC tumor stage, and surgical style; (6) patients died within 3 months after surgery; (7) patients withoutprognostic information. The remaining patients were enrolled as SEER primary cohort.

Covariates and endpoints
------------------------

Patients' characteristics were analyzed according to the following 9 factors: age (\<40, 40--60, or \>60 years), race (white, black, or other), marital status (married, unmarried, unknown), tumor grade (Grade I/II, Grade III/IV, unknown), AJCC stage (IIIA, IIIB, IV), breast Subtype (Her2-/hormone receptor (HoR)+, Her2+/HoR-, Her2+/HoR+, Triple Negative, unknown); surgery (simple mastectomy, radical mastectomy), chemotherapy (no/unknown, yes), PMRT (no/unknown, yes). The widowed or single (having a domestic partner or never married) or separated or divorced were classified as unmarried. Age was further transformed into a categorical variable according to recognized cut-off values. Race was divided into white, black and other (including Asian/Pacific Islander, American Indian/Alaska native, and unknown). A simple mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done. A radical mastectomy removes all breast tissue, the nipple, the areolar complex, and variable amounts of breast skin, which includes axillary lymph node dissection. In addition, all eligible subjects were restaged in accordance with the 8th AJCC TNM staging system. The HoR status of tumor was stratified into HoR-positive \[ER+/PR+, ER-/PR+, and ER+/PR-\] and HoR-negative (ER-/PR-). The definition of ER/PR+ disease was ofor over 1% cells stained positive ([@ref-19]). Our research was limited to between 2010 and2013 because breast subtype was published from 2010 in the SEER database.

The primary endpoints in this research were overall survival (OS) as well as cancer-specific survival (CSS). CSS was defined as the interval from diagnosis to the last follow-up or death caused by IBC.OS was defined as the duration from diagnosis to the last follow-up or death. There was a predetermined cut-off date based on the SEER 2016 submission database, containing death information until 2014. Therefore, a cut-off date of December 31, 2014 was utilized in our study.

Propensity score matching (PSM)
-------------------------------

In observational research, selection bias is unavoidable, leading to unevenly distributed confounding factors between two groups. A PSM is defined as the conditional possibility of assignment to a certain treatment given a vector of observed covariates ([@ref-22]). Thus, in order to decrease selection bias as well as unevenly distributed confounding factors, the PSM method was employed in this research ([@ref-27]). The logistic regression model was used to estimate propensity scores of all patients by enrolling all covariates potentially affecting patient survival, followed by the PSM plug-in of the SPSS software to estimate the propensity score of every case. PSM was performed afterward using 1:1 nearest-neighbor matching with a caliper of0.05 to obtain a matched pair. PSM was conducted between the PMRT group and the No-PMRT group of each subgroup.

Statistical analyses
--------------------

Pearson's *χ*2 or Fisher's exact tests were utilized for comparison of clinicopathologic characteristics before and after PSM. Kaplan--Meier (K-M) method was utilized for estimation of the univariate analysis, along with the log-rank test to assess the differences of CSS and OS. Moreover, the risk of mortality was assessed by multivariate Cox proportional hazards regression models, which were also used for subgroup analyses. Variables with potential significance in the univariate analysis (*P* \< 0.05) or clinically regarded as prognostic factors were further enrolled in multivariate analysis. All statistical analyses were conducted using SPSS software (SPSS Inc., Chicago, USA, version 19.0). Graph Pad Prism 5 was employed to generate the survival curve and forest plots. A two-sided *P* \< 0.05 was considered as statistically significant.

Results
=======

Patient characteristics before and after PSM
--------------------------------------------

In total, 293 cases were enrolled in this research. According to whether the patients received PMRT, two groups were defined: No-PMRT group (*n* = 108) and PMRT group (*n* = 185).The specific screening process was shown in [Fig. 1](#fig-1){ref-type="fig"}. Patient characteristics in both cohorts were presented in [Table 1](#table-1){ref-type="table"}. Only two patients had bilateral breast cancer. The median follow-up duration of all subjects was 27 months (5--59 months).The following variables, age, tumor grade, race, marital status, AJCC stage, breast subtype; surgery style and chemotherapy were included in PSM. The plot of the propensity distribution score was shown in [File S1](#supp-1){ref-type="supplementary-material"}. Specifically, the PMRT group had a higher proportion of married and received chemotherapy before PSM. After PSM at a 1:1 ratio, there were 94 patients in each group, and all the baseline characteristics of the two groups were balanced.

![Flow chart for screening eligible patients.](peerj-08-8512-g001){#fig-1}
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###### Baseline characteristics before and after propensity score matching (PSM).
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  Variables            Before PSM    After PSM                                            
  -------------------- ------------- -------------- --------- ------------- ------------- -------
  Age                                               0.921                                 0.483
  \<40                 14 (12.96%)   27 (14.59%)              11 (11.70%)   11 (11.70%)   
  40--60               59 (54.63%)   98 (52.97%)              56 (59.57%)   63 (67.02%)   
  \>60                 35 (32.41%)   60 (32.43%)              27 (28.72%)   20 (21.28%)   
  Race                                              0.507                                 0.270
  White                82 (75.93%)   151 (81.62%)             69 (73.40%)   78 (82.98%)   
  Black                16 (14.81%)   21 (11.35%)              16 (17.02%)   11 (11.70%)   
  Other                10 (9.26%)    13 (7.03%)               9 (9.57%)     5 (5.32%)     
  Marital status                                    0.007                                 0.127
  Married              44 (40.74%)   109 (58.92%)             40 (42.55%)   53 (56.38%)   
  Unmarried            56 (51.85%)   70 (37.84%)              46 (48.94%)   37 (39.36%)   
  Unknown              8 (7.41%)     6 (3.24%)                8 (8.51%)     4 (4.26%)     
  Grade                                             0.081                                 0.079
  Grade I/II           24 (22.22%)   51 (27.57%)              19 (20.21%)   30 (31.91%)   
  Grade III/IV         69 (63.89%)   94 (50.81%)              60 (63.83%)   45 (47.87%)   
  Unknown              15 (13.89%)   40 (21.62%)              15 (15.96%)   19 (20.21%)   
  AJCC stage                                        0.088                                 0.082
  IIIA                 62 (57.41%)   124 (67.03%)             52 (55.32%)   61 (64.89%)   
  IIIB                 17 (15.74%)   31 (16.76%)              13 (13.83%)   17 (18.09%)   
  IV                   29 (26.85%)   30 (16.22%)              29 (30.85%)   16 (17.02%)   
  Breast Subtype                                    0.976                                 0.805
  Her2-/HR+            37 (34.26%)   65 (35.14%)              30 (31.91%)   31 (32.98%)   
  Her2+/HR-            17 (15.74%)   32 (17.30%)              15 (15.96%)   11 (11.70%)   
  Her2+/HR+            22 (20.37%)   38 (20.54%)              20 (21.28%)   26 (27.66%)   
  Triple Negative      25 (23.15%)   41 (22.16%)              23 (24.47%)   20 (21.28%)   
  Unknown              7 (6.48%)     9 (4.86%)                6 (6.38%)     6 (6.38%)     
  Surgery                                           0.069                                 0.154
  Simple Mastectomy    33 (30.56%)   39 (21.08%)              24 (25.53%)   16 (17.02%)   
  Radical mastectomy   75 (69.44%)   146 (78.92%)             70 (74.47%)   78 (82.98%)   
  Chemotherapy                                      \<0.001                               1.000
  No/unknown           16 (14.81%)   3 (1.62%)                3 (3.19%)     3 (3.19%)     
  Yes                  92 (85.19%)   182 (98.38%)             91 (96.81%)   91 (96.81%)   

**Notes.**

AbbreviationsHoRHormone receptorPSMpropensity score matchingPMRTpostmastectomy radiotherapy

CSS and OS of patients before and after PSM
-------------------------------------------

Before PSM, patients in the PMRT group showed significantly higher 1- and 3-year OS rates than those in the No-PMRT group (97.8%, 70.2%, respectively vs. 87.8% and 56.0%, respectively; *P* = 0.034) ([Fig. 2B](#fig-2){ref-type="fig"}). However, there was no difference of1-and 3-year CSS between the two groups (97.8%, 70.1%, respectively vs. 89.5%, 60.1%, respectively; *P* = 0.13) ([Fig. 2A](#fig-2){ref-type="fig"}). After PSM, patients in the PMRT group harbored significantly higher 1- and 3-year CSS and OS rates \[CSS (99.0%, 81.8% vs. 89.1% and 59.7%, respectively, *P* = 0.013); OS (99.0%, 81.8% vs. 88.2% and 58.2%, respectively, *P* = 0.0063)\] ([Fig. 3](#fig-3){ref-type="fig"}).

Prognostic factors for survival after PSM
-----------------------------------------

Multivariate analysis of CSS and OS revealed that black ethnicity\[CSS (HR:2.251, 95% CI \[1.186--4.271\], *P* = 0.029); OS (HR:2.076, 95% CI \[1.102--3.912\], *P* = 0.024)\], AJCC stage IV \[CSS (HR:4.837, 95% CI \[2.548--9.180\], *P* \< 0.001); OS (HR:4.475, 95% CI \[2.387--8.389\])\] and triple negative subtype \[CSS (HR:3.387, 95% CI \[1.697--6.762\], *P* = 0.001); OS (HR:3.188, 95% CI \[1.630--6.235\], *P* = 0.001)\] were independent unfavorable prognostic factors, and Her2+/HR+ subtype \[CSS (HR:0.244, 95% CI \[0.070--0.857\], *P* = 0.028); OS (HR:0.225, 95% CI \[0.065--0.785\], *P* = 0.019)\] and PMRT \[CSS (HR:0.519, 95% CI \[0.287--0.939\], *P* = 0.030); OS (HR:0.480, 95% CI \[0.269--0.859\], *P* = 0.013)\] were independent favorable prognostic factors ([Table 2](#table-2){ref-type="table"}).

![Kaplan--Meier curves for CSS and OS before PSM.\
Cancer-specific survival (A) and overall survival (B) differences between postmastectomy radiotherapy (PMRT) and No-PMRT groups, before 1:1 Propensity Score Matching analysis. *P* = 0.13 for PMRT group compared to No-PMRT group for CSS; \**P* = 0.034 for PMRT group compared to No-PMRT group for OS.](peerj-08-8512-g002){#fig-2}

![Kaplan--Meier curves for CSS and OS after PSM.\
Cancer-specific survival (A) and overall survival (B) differences between postmastectomy radiotherapy (PMRT) and No-PMRT groups, after 1:1 Propensity Score Matching analysis. \**P* = 0.013 for PMRT group compared to No-PMRT group for CSS; \*\**P* = 0.0063 for PMRT group compared to No-PMRT postmastectomy RT (PMRT) group for OS.](peerj-08-8512-g003){#fig-3}

Subgroup analysis for OS and CSS after PSM
------------------------------------------

Subgroup analysis of CSS and OS demonstrated that nearly all study population could benefit survival from PMRT except those with stage IV ([Figs. 4](#fig-4){ref-type="fig"} and [5](#fig-5){ref-type="fig"}). Married patients could obtain significant benefit from PMRT in terms of CSS (HR: 0.32, 95% CI \[0.11--0.89\], *P* = 0.029). In addition, patients who aged 40--60 (HR: 0.39, 95% CI \[0.17--0.90\], *P* = 0.027), married (HR: 0.32, 95% CI \[0.11--0.89\], *P* = 0.029), and chemotherapy (HR: 0.50, 95% CI \[0.26--0.95\], *P* = 0.035) also acquired significant benefit from PMRT, in terms of OS.
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###### Univariate and multivariate analyses of cancer special survival (CSS) and overall survival (OS) after propensity score matching (*N* = 188).
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  Variables            CSS       OS                                                                  
  -------------------- --------- ----------------------- --------- --------- ----------------------- ---------
  Age                  0.407                             NI        0.491                             NI
  \<40                                                                                               
  40--60                                                                                             
  \>60                                                                                               
  Race                 0.002                             0.029     0.003                             0.046
  White                          Reference                                   Reference               
  Black                          2.251 (1.186, 4.271)    0.013               2.076 (1.102, 3.912)    0.024
  Other                          0.781 (0.270, 2.258)    0.648               0.725 (0.252.2.084)     0.551
  Marital status       0.204                             NI        0.138                             NI
  Married                                                                                            
  Unmarried                                                                                          
  Unknown                                                                                            NI
  Grade                0.108                             NI        0.078                             
  Grade I/II                                                                                         
  Grade III/IV                                                                                       
  Unknown                                                                                            
  AJCC stage           \<0.001                           \<0.001   \<0.001                           \<0.001
  IIIA                           Reference                                   Reference               
  IIIB                           1.465 (0.645, 3.328)    0.361               1.541 (0.702, 3.380)    0.281
  IV                             4.837(2.548, 9.180)     \<0.001             4.475(2.387, 8.389)     \<0.001
  Breast Subtype       \<0.001                           \<0.001   \<0.001                           \<0.001
  Her2-/HoR+                     Reference                                   Reference               
  Her2+/HoR-                     0.870 (0.330, 2.294)    0.778               0.820 (0.314, 2.143)    0.686
  Her2+/HoR+                     0.244 (0.070, 0.857)    0.028               0.225 (0.065, 0.785)    0.019
  Triple Negative                3.387 (1.697, 6.762)    0.001               3.188 (1.630, 6.235)    0.001
  Unknown                        1.988 (0.655, 6.036)    0.225               1.897 (0.633, 5.685)    0.253
  Surgery              0.843                             0.307     0.738                             0.254
  Simple Mastectomy              Reference                                   Reference               
  Radical mastectomy             1.493 (0.692, 3.222)                        1.556 (0.728, 3.323)    
  Chemotherapy         0.459                             0.637     0.438                             0.549
  No/unknown                     Reference                                   Reference               
  Yes                            1.641 (0.209, 12.882)                       1.875 (0.241, 14.607)   
  PMRT                 0.013                             0.030     0.006                             0.013
  No                             Reference                                   Reference               
  Yes                            0.519 (0.287, 0.939)                        0.480 (0.269, 0.859)    

**Notes.**

AbbreviationHoRHormone receptorCSScancerspecific survivalOSoverall survivalNInot included in the multivariate survival analysisPMRTpost mastectomy radiotherapy

Discussion
==========

To our knowledge, it is the first large population-based analysis to evaluate the survival benefit of PMRT in treating IBC patients, along with the application of PSM.A total of 293 eligible cases were analyzed in our study. We found that patients in the PMRT group had significant survival benefit after PSM. Additionally, PMRT was an independent favorable prognostic factor for CSS and OS. Further subgroup analysis revealed that nearly all subgroup population could benefit from PMRT.

![Forest plot of subgroup analysis for CSS after PSM.\
Subgroup analysis of cancer-specific survival between postmastectomy radiotherapy (PMRT) and No-PMRT groups, after 1:1 Propensity Score Matching analysis. Nearly all subgroups derived CSS benefit in favor of PMRT, except AJCC stage IV and CS extension ≥50%.](peerj-08-8512-g004){#fig-4}

![Forest plot of subgroup analysis for OS after PSM.\
Subgroup analysis of OS between postmastectomy radiotherapy (PMRT) and No-PMRT groups, after 1:1 Propensity Score Matching analysis. Nearly all subgroups derived OS benefit in favor of PMRT group, except AJCC stage IV and CS extension ≥50%.](peerj-08-8512-g005){#fig-5}

More effective neoadjuvant therapy has enhanced the clinical response rate, and additionally, a considerable percentage of the previously unresectable subjects are proper for mastectomy ([@ref-6]; [@ref-10]; [@ref-34]). Despite the incompletely validated survival benefit of PMRT, the advances in loco-regional control render PMRT on the thoracic wall and regional lymph nodes as an optional therapeutic option ([@ref-1]; [@ref-9]). However, PMRT is underused in clinical practice. By utilizing the 1998 to 2011 National Cancer Data Base, a study conducted by MD Anderson Cancer Center revealed that 8273 females undergoing mastectomy for non-metastatic IBC ([@ref-23]). Among those patients, over 30% did not undergo PMRT, mainly due to patients' choice (86.4%), as well as other reasons including treatment at lower-volume centers, annual income, restricted coverage from medical insurance and distance between patient's residence and radiotherapy facility ([@ref-2]). Moreover, the non-receipt of PMRT rate for non-inflammatory but loco-regionally advanced breast cancer recorded in the literature was even higher, varying from approximately 35% to 50% ([@ref-11]; [@ref-29]).Therefore, this study is designed, aiming at that more patients and doctors can realize the significance of PMRT in IBC by confirming the survival benefits of PRMT.

At present, there are no established risk factors for IBC. However, multiple epidemiological studies have clarified the characteristics of IBC ([@ref-32]). The most important suspected risk factors associated with IBC include black race, body mass index(BMI), and age ([@ref-8]). Additionally, Wu et al. found that breast cancer subtype was clinically useful to predict survival outcome in IBC. Patients with HoR-/HER2- subtype had significantly poorer OS compared to the other three subtypes. While patients with HoR+/HER2+ subtype harbored more favorableOS than the HoR+/HER2- subtype ([@ref-33]), which are consistent with our findings. However, age was not found to be a risk factor for prognosis in our study.

Our study found that radiotherapy is an independent prognostic risk factor for IBC. Some scholars have come to the same conclusion as ours. Diao et al. established and validated the prognostic model of IBC patients. From January 2004 to December 2013, 1,651 patients were enrolled in this study. Surgery, radiotherapy, and chemotherapy were all independent prognostic risk factors for IBC patients, indicating that multimodal comprehensive treatment could benefit IBC patients significantly ([@ref-14]). Similar results were also obtained in Pan X's study ([@ref-26]). Comparing the two studies with ours, our enrollment was significantly smaller, mainly because our research time span was from 2010 to 2013.The main reason for choosing this time range is that the HER-2 factor was not available prior to 2010 in the SEER database. Breast cancer subtypes have been shown to be an independent prognostic risk factor for inflammatory breast cancer ([@ref-17]; [@ref-33]), so it is necessary to include the factor. However, such a short time range of enrollment also directly leads to less enrollment and shorter follow-up time in our study.

There are certain limitations to our research. First, as an observational study, the possibility of bias might be inevitable. Though the PSM method was used to decrease the bias resulting from unevenly-distributed measured covariates, it is unavoidable that unmeasured factors might cause bias. Second, there is a sizeable amount of missing data in the SEER dataset which can result in bias. Third, radiotherapy field design and dose may influence disease recurrence and survival outcome ([@ref-28]); however, SEER does not record radiotherapy treatment details. In addition, the median follow-up time of 27 months in our study is too short to accurately reflect the long-term survival outcomes of IBC. Moreover, there are inaccuracies in the SEER database, with high rates of under-reporting for receipt of radiotherapy and chemotherapy ([@ref-20]; [@ref-24]). For this reason, we have adopted many methods to remedy these defects. Schoenfeld residual test was used to prove the proportional-hazard assumption of Cox model. Results revealed that all variables and the whole model were consistent with the hypothesis (all *P* \> 0.05). In addition, we adopted the R software (version 3.6) making use of the "MICE" package for data imputation. Data with missing value (less than 20%) were imputed using the Multivariable Imputation by Chained Equations algorithm as described in [@ref-30]. Although obtaining more details is preferable, our aim is to demonstrate the general survival advantage of PMRT for IBC patients. Thus, the currently accessible data in the SEER dataset meet our research design and objectives.

Conclusion
==========

Our findings have validated the survival benefits of PMRT for IBC patients, which might optimize the present individualized therapeutic strategies for specific populations. Further prospective clinical trials are still needed to validate our findings.
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